|
1. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 2023; 17;8:70. doi: 10.1038/s41392-023-01332-8. 2. Colomer‐Lahiguera S, Steimer M, Ellis U, Eicher M, Tompson M, Corbière T, et al. Patient and public involvement in cancer research: A scoping review. Cancer Med 2023; 16. doi: 10.1002/cam4.6200. 3. Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res 2018;7: 1-10. doi: 10.12688/f1000research.13179.1. 4. Safarpour-Dehkordi M, Doosti A, Jami MS. Integrative analysis of lncRNAs in kidney cancer to discover a new lncRNA (LINC00847) as a therapeutic target for staphylococcal enterotoxin tst gene. Cell J 2020;22:101. doi: 10.22074/cellj.2020.6996. 5. Jin L, Quan J, Pan X, He T, Hu J, Li Y, et al. Identification of lncRNA EGOT as a tumor suppressor in renal cell carcinoma. Mol Med Rep 2017;16:7072-9. doi: 10.3892/mmr.2017.7470. 6. Guo Z, Wang YH, Xu H, Yuan CS, Zhou HH, Huang WH, et al. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma. Cell Death Dis 2021;12:69. doi: 10.1038/s41419-020-03302-2. 7. Li M, Wang Y, Cheng L, Niu W, Zhao G, Raju JK, et al. Long non-coding RNAs in renal cell carcinoma: a systematic review and clinical implications. Oncotarget 2017;8:48424-35.doi: 10.18632/oncotarget.17053. 8. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009; 625:190-4. doi:10.1016/j.ejphar.2009.08.043. 9. Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC. Structure–activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A 2000; 97:8245-50. doi: 10.1073/pnas.150518097. 10. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett 2008; 271:47-55. doi: 10.1016/j.canlet.2008.05.041. 11. Safarpour M, Kazemi Z, Doosti E, Doosti A. Cloning tagD gene from helicobacter pylori in PFLAG-CMV-3 eukaryotic vector to generate a DNA vaccine. JIUMS 2016; 14:43-50. 10.29252/JMJ.14.4.43. 12. Seim I, Jeffery PL, Thomas PB, Walpole CM, Maugham M, Fung JN, et al. Multi-species sequence comparison reveals conservation of ghrelin gene-derived splice variants encoding a truncated ghrelin peptide. Endocrine 2016; 52:609-17. doi: 10.1007/s12020-015-0848-7. 13. Safarpour-Dehkordi M, Samimi-Dehkordi N, Asgari M, Khademi R, Kabirian-Dehkordi M, Amiri M, et al. Co-expression network analysis for the identification of potential prostate cancer genes and in vitro confirmation of their expression in cell model in the presence of Staphylococcal tsst-1 gene. Nucleosides Nucleotides Nucleic Acids 2023; 17:1-6. doi:10.1080/15257770.2023.2249544. 14. Safarpour-Dehkordi M, Doosti A, Jami MS. Impacts of the Staphylococcal Enterotoxin H on the Apoptosis and lncRNAs in PC3 and ACHN. Mol Gen Microbiol Virol 2020; 35:180-8. doi: 10.3103/S0891416820030076. 15. Li H, Li X, Bai M, Suo Y, Zhang G, Cao X. Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2. Int J Clin Exp Patho 2015; 8:14793. 16. Zhou M, Zou X, Cheng K, Zhong S, Su Y, Wu T, et al. The role of cell‐penetrating peptides in potential anti‐cancer therapy. Clin Transl Med 2022;12: e822. doi: 10.1002/ctm2.822. 17. Vakili B, Jahanian-Najafabadi A. Application of Antimicrobial Peptides in the Design and Production of Anticancer Agents. Int J Pept Res Ther 2023; 20; 29:28. 18. Parker JP, Devocelle M, Morgan MP, Marmion CJ. Derivatisation of buforin IIb, a cationic henicosapeptide, to afford its complexation to platinum (ii) resulting in a novel platinum (ii)–buforin IIb conjugate with anti-cancer activity. Dalton Trans 2016;45:13038-41. doi: 10.1039/c6dt01510g. 19. Li M, Wang Y, Cheng L, Niu W, Zhao G, Raju JK, et al. Long non-coding RNAs in renal cell carcinoma: a systematic review and clinical implications. Oncotarget 2017; 7; 8:48424. doi: 10.18632/oncotarget.17053.
|
